lung cancer trial fails, page-10

I hope you're not about to tell me that this company might be able to make a profit. Even with it missing not only the primary endpoint in its latest trial, but also a number of secondary endpoints? I mean, this drug looks like a dud.

Anyway, if what you're implying is true, then I would have to raise my price target. How much it goes above cash value would depend on your sage advice.